Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

Panayiotis Panayiotidis,Gayane Tumyan,Catherine Thieblemont,Vadim V Ptushkin,Ana Marin Niebla,Ramon Garcia-Sanz,Andrey Zaritskey,Steven Le Gouill,Christian Buske,Marlies Van Hoef,Thomas Perretti,Monique S Tomiczek,Anastasios Stathis

doi:10.1182/blood-2020-137087

Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

Panayiotis Panayiotidis, Gayane Tumyan + Show 11 more

Open Access

https://doi.org/10.1182/blood-2020-137087

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 1

Affiliation: Russian Cancer Research Center NN Blokhin, Roche (Switzerland), Centre d'Investigation Clinique de Nantes, Centre Hospitalier Universitaire de Nantes, Nantes Université, Inserm, University Hospital Ulm, Federal Almazov North-West Medical Research Centre, Botkin Hospital, Vall d'Hebron Hospital Universitari, Institute of Oncology Research, National and Kapodistrian University of Athens

#Mantle Cell Lymphoma Pts #Mantle Cell Lymphoma Groups + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

Full Text